Can I Take Creatine With Amlodipine?

How Amlodipine Works and Why Kidneys Are Relevant

Amlodipine is a third-generation dihydropyridine calcium channel blocker approved by the FDA for hypertension and chronic stable or vasospastic angina. [1] It blocks L-type voltage-gated calcium channels in vascular smooth muscle, reducing peripheral vascular resistance and lowering blood pressure without directly suppressing cardiac contractility at therapeutic doses.

The drug is almost entirely metabolized in the liver via CYP3A4 and excreted as inactive metabolites in urine. Less than 10% of a dose leaves the body as unchanged drug. [2] That matters here because amlodipine's clearance does not depend on glomerular filtration rate in the way that renally cleared drugs like metformin or lisinopril do.

Why Kidney Function Still Matters for Amlodipine Patients

Even though amlodipine is not renally cleared, patients taking it are almost always being treated for hypertension, and chronic hypertension is a leading cause of chronic kidney disease (CKD). The National Kidney Foundation estimates that high blood pressure accounts for roughly 26% of kidney failure cases in the United States. [3] Clinicians managing these patients watch creatinine trends carefully.

A stable serum creatinine is a reassuring sign that blood pressure control is protecting kidneys. A rising creatinine triggers investigation. If creatine supplementation raises creatinine without any real change in kidney function, that false signal can send a patient through unnecessary testing or, worse, prompt a medication change that was not needed.

Amlodipine's Mild Renoprotective Effect

Some evidence suggests dihydropyridines like amlodipine provide modest renal protection beyond blood pressure lowering alone. The ALLHAT trial (N=33,357) found amlodipine-based therapy comparable to lisinopril-based therapy on combined cardiovascular and renal outcomes over 4.9 years. [4] Neither drug caused meaningful renal deterioration on its own. This context is worth holding: amlodipine is not nephrotoxic, so the conversation about creatine centers on lab interpretation rather than direct kidney damage.

What Creatine Does Inside the Body

Creatine is an amino acid derivative synthesized endogenously from arginine, glycine, and methionine, primarily in the liver and kidneys. About 95% of the body's creatine pool resides in skeletal muscle as free creatine or phosphocreatine. [5] Supplementing with exogenous creatine monohydrate increases muscle phosphocreatine stores, which accelerates ATP resynthesis during short, high-intensity efforts.

The Creatine-to-Creatinine Conversion

Both endogenous creatine and supplemental creatine degrade non-enzymatically to creatinine at a rate proportional to total body creatine pool size. Adding 3-5 g/day of supplemental creatine monohydrate expands the muscle creatine pool and raises daily creatinine production. This is a biochemical certainty, not a theoretical concern.

A 2003 crossover study published in the Journal of the American Society of Nephrology (N=18 healthy males) measured serum creatinine at baseline and after 5 days of creatine loading at 20 g/day followed by 30 days of 5 g/day maintenance. Serum creatinine rose from a mean of 0.9 mg/dL to 1.2 mg/dL during loading and settled at approximately 1.0 mg/dL on maintenance. [6] Glomerular filtration rate measured by inulin clearance did not change, confirming the rise was a production artifact, not impaired filtration.

Does Creatine Cause Actual Kidney Damage?

Short answer: almost certainly not in people with healthy kidneys. A 2021 systematic review in the Journal of the International Society of Sports Nutrition analyzed 15 randomized controlled trials and found no clinically significant changes in GFR, urinary albumin, or cystatin C with creatine supplementation at doses of 3-20 g/day across durations of 5 days to 5 years. [7]

The picture is less clear in people with pre-existing CKD. The kidneys are involved in endogenous creatine synthesis, and some researchers have proposed that loading the system with exogenous creatine may increase metabolic demand on already-stressed nephrons. Direct human evidence in CKD patients remains sparse. Caution is warranted at stages 3 through 5.

The Specific Interaction Between Creatine and Amlodipine

There is no documented pharmacokinetic interaction between creatine and amlodipine. Creatine does not inhibit or induce CYP3A4, P-glycoprotein, or any transporter relevant to amlodipine absorption or clearance. [8] Amlodipine does not affect creatine uptake into muscle, phosphocreatine resynthesis, or renal creatinine secretion.

The interaction is pharmacodynamic only, and indirect at that. The chain of concern runs like this:

1. Amlodipine patient has blood pressure-related kidney vulnerability.
2. Creatine supplementation raises serum creatinine without changing true GFR.
3. Clinician sees a creatinine of 1.4 mg/dL (previously 1.0 mg/dL) on routine labs.
4. Without knowing about the creatine supplementation, the clinician suspects worsening nephropathy.
5. Additional workup, possible dose adjustments, or referral follows.

This scenario is preventable with a single conversation.

Cystatin C as a Workaround

Cystatin C is a kidney filtration marker produced at a constant rate by all nucleated cells and filtered entirely by the glomerulus. Unlike creatinine, cystatin C is not derived from creatine metabolism and is not affected by muscle mass or creatine supplementation. [9]

If a patient on amlodipine begins creatine and their creatinine rises, ordering a serum cystatin C test provides a clean picture of actual filtration. A stable cystatin C alongside a rising creatinine is strong evidence the rise is supplementation-related rather than pathological.

Blood Pressure Effects: Any Concern?

Creatine has no consistent effect on resting blood pressure in normotensive or hypertensive adults. A meta-analysis of 12 RCTs (N=281 participants) published in Nutrition in 2021 found mean systolic blood pressure changes of 0.4 mmHg with creatine vs. Placebo, a difference that was not statistically significant. [10] So creatine is unlikely to undermine amlodipine's antihypertensive effect.

Who Should Be Most Careful

Most people taking amlodipine for uncomplicated hypertension and who have a normal baseline eGFR can add creatine with standard monitoring. Three groups need a more careful approach.

Patients With CKD Stage 3 or Higher

An eGFR below 60 mL/min/1.73m² puts a patient in CKD stage 3. At this level, the kidneys are already operating with reduced reserve. The International Society of Renal Nutrition and Metabolism advises restricting dietary creatine-containing foods (primarily red meat) in advanced CKD because the protein load and creatinine production can complicate fluid and waste management. [11] Creatine supplementation adds a meaningful creatinine load on top of diet. For these patients, the risk-benefit calculation requires a nephrology consultation.

Patients on Concurrent ACE Inhibitors or ARBs

Some patients take amlodipine alongside an ACE inhibitor (like lisinopril) or an angiotensin receptor blocker (like losartan) as combination antihypertensive therapy. Both of those drug classes reduce efferent arteriolar tone and can raise creatinine independently by 10-15% from baseline. [12] If creatine adds another 10-20% bump, the combined creatinine rise may look alarming even though glomerular filtration is stable. Cystatin C measurement becomes especially useful in this subgroup.

Athletes Using Loading Protocols

The standard loading phase of 20 g/day for 5-7 days produces the largest and fastest creatinine elevation. Patients who want to skip loading and go directly to a 3-5 g/day maintenance dose will see a smaller, slower rise that is easier to interpret on labs. For patients on antihypertensives, skipping the loading phase is a reasonable, low-cost risk reduction.

Monitoring Protocol for Patients Taking Both

The following stepwise monitoring approach is used by the HealthRX clinical team when evaluating patients who take amlodipine and wish to add creatine supplementation.

Step 1. Baseline labs before starting creatine. Order a basic metabolic panel (BMP) or comprehensive metabolic panel (CMP) to capture serum creatinine, BUN, eGFR, and electrolytes. If the patient is also on an ACE inhibitor or ARB, include a spot urine albumin-to-creatinine ratio.

Step 2. Choose maintenance dosing over loading. Start at 3-5 g creatine monohydrate per day. Skip the 20 g/day loading phase to keep the creatinine trajectory gradual and interpretable.

Step 3. Repeat BMP at 4-6 weeks. A rise of 0.1-0.3 mg/dL in serum creatinine with an otherwise unremarkable panel is consistent with creatine-related creatinine production. No medication changes are needed.

Step 4. Order cystatin C if creatinine rises more than 0.3 mg/dL. Cystatin C helps distinguish a production-related creatinine rise from genuine filtration decline.

Step 5. Hydration reminder. Creatine draws water into muscle cells. Advise patients to maintain adequate daily fluid intake, roughly 35-45 mL/kg/day, to avoid any transient reduction in renal perfusion from dehydration. This is particularly relevant in patients with baseline cardiovascular disease where diuretics may already reduce circulating volume.

Step 6. Annual labs as long as the patient continues creatine. Incorporate creatinine and eGFR into the patient's standard annual cardiovascular metabolic panel.

Evidence Quality and Guideline Positions

The American College of Sports Medicine's 2017 Position Stand on creatine notes that "creatine supplementation does not adversely affect kidney function in healthy individuals" and acknowledges that the creatinine-elevation artifact is well-established. [13] The statement does not address combined use with antihypertensive drugs specifically, which reflects the fact that no dedicated trial has studied this combination.

The FDA's label for amlodipine besylate (NDA 019787) lists no known interactions with dietary supplements and identifies no renal dosing adjustment requirement, reinforcing that the drug itself is not the problem. [1]

A 2019 Cochrane review on interventions for CKD management noted that creatine metabolism contributes meaningfully to serum creatinine variability across study populations, a point relevant to any clinician trying to track CKD progression in a patient who supplements. [14]

The gap in the literature is direct: no randomized trial has co-enrolled amlodipine patients and creatine users to track renal outcomes. The guidance above is built from mechanism, from each agent's individual trial data, and from the monitoring principles embedded in hypertension and nephrology guidelines.

Practical Guidance: What to Tell Your Prescriber

Before adding creatine, tell your prescribing clinician you plan to start it. This is a short conversation with outsized benefit. Specifically, mention:

• The brand and dose of creatine you plan to use.
• Whether you intend to use a loading phase.
• Any symptoms of poor kidney function you have noticed (swelling in legs, foamy urine, decreased urine output).

Your prescriber may order a BMP before you begin. If your creatinine is already near the upper end of the normal range (around 1.2 mg/dL for men, 1.0 mg/dL for women), they may want to track more frequently or recommend skipping supplemental creatine altogether in favor of dietary sources.

The interaction here is manageable. It is not a hard contraindication. The patients most likely to benefit from this conversation are those already on multiple antihypertensive agents, those with a known eGFR below 60, or those in competitive sports settings where loading doses are common practice.

Creatine Forms and Whether They Change the Equation

The market offers creatine monohydrate, creatine hydrochloride (HCl), buffered creatine (Kre-Alkalyn), creatine ethyl ester, and micronized creatine, among others. Only creatine monohydrate has a substantial evidence base. [7]

Creatine HCl and buffered forms are marketed as producing less gastrointestinal discomfort and requiring lower doses for the same effect. If the dose is genuinely lower for equivalent muscle saturation, the creatinine rise may be smaller. That claim has not been confirmed in head-to-head pharmacokinetic trials at the time of this writing. Patients should not assume an alternative form eliminates the creatinine-elevation concern without lab confirmation.

Drug Interactions Amlodipine Already Carries

For completeness, note that amlodipine does have well-characterized interactions with several agents that are not creatine. Strong CYP3A4 inhibitors, including clarithromycin, ketoconazole, and grapefruit juice, can raise amlodipine plasma concentrations by 50-100% and warrant dose review. [2] CYP3A4 inducers like rifampin reduce amlodipine exposure. These are the interactions a prescriber will prioritize when reviewing a patient's full medication and supplement list.

Creatine sits well outside this interaction category. Patients sometimes worry unnecessarily about the combination after reading general warnings about supplements and blood pressure medications. The actual concern is narrow and lab-based, not pharmacological.